Preventing Skin Cancer (Nicotinamide)

We are delighted that he results of the Oral Nicotinamide To Reduce Actinic Cancer (ONTRAC) are now public. We have shown that Nicotinamide decreases the number of skin cancers (basal cell carcinoma and squamous cell carcinoma) in high risk patients. Westmead Dermatology is one of the two sites that participated in the Clinical Trial, Bonita Choi was the researcher responsible for the trial, and she is the third author of the now published abstract.
Patients on nicotinamide for 1 year developed 1.77 new skin cancers compared with patients on placebo, that developed 2.42 new skin cancers. We conclude that “nicotinamide reduces NMSC formation in high risk patients and is well tolerated. Furthermore, it is widely accessible as an inexpensive over-the-counter vitamin supplement and presents a new chemopreventive opportunity against NMSCs that is readily translatable into clinical practice.”